SCHEDULE: RA Capital Discloses 8.9% Stake in Vaxcyte

RA Capital Management and its principals have reported an 8.9% beneficial ownership stake in Vaxcyte, Inc. as of March 31, 2026.

Summary

• RA Capital Management, L.P., along with Peter Kolchinsky and Rajeev Shah, reported beneficial ownership of 12,974,599 shares of Vaxcyte, Inc. common stock.
• The reported stake represents 8.9% of the company's outstanding common stock.
• The holdings include 11,199,089 shares held by the RA Capital Healthcare Fund, 1,500,000 shares issuable upon exercise of pre-funded warrants, and 275,510 shares held by the RA Capital Nexus Fund.
• The reporting persons maintain shared voting and dispositive power over these securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral regulatory filing that confirms existing institutional support without indicating new strategic shifts.

Positives

• Continued institutional support from a specialized healthcare investment firm.
• The filing confirms the firm's ongoing investment interest in Vaxcyte's long-term potential.

Negatives

• None identified; this is a standard regulatory disclosure of existing holdings.

Risks

• The investment is subject to market volatility and the inherent risks associated with biotechnology development.
• The reporting persons disclaim any intent to change or influence the control of the issuer.

Future Outlook

The filing does not provide forward-looking guidance on the company's operations, as it is a disclosure of beneficial ownership by an institutional investor.

Industry Context

StockSavvy.ai notes that RA Capital is a prominent life sciences investor; their continued significant stake in Vaxcyte signals institutional confidence in the company's vaccine pipeline and clinical progress.

Comparison to Industry Standards

• The filing is consistent with standard institutional reporting requirements for biotech firms.
• The level of ownership is typical for specialized healthcare funds maintaining long-term positions in clinical-stage companies.

Stakeholder Impact

• Provides transparency to shareholders regarding the concentration of institutional ownership.

Next Steps

• Continued monitoring of future 13G or 13F filings for changes in institutional positioning.

Key Dates

Keywords

Vaxcyte, RA Capital, 13G, Biotech, Institutional Ownership, Vaccine Development